BCAAs

BCAAs are three of the nine essential amino acids: leucine, isoleucine and valine. They are grouped because they share a branched molecular structure and, unusually, because they are metabolised largely in skeletal muscle rather than the liver.

Supplements typically use a 2:1:1 ratio of leucine to isoleucine to valine, roughly reflecting their proportion in muscle tissue. Higher leucine ratios such as 4:1:1 and 8:1:1 have been marketed, but there is no good evidence they outperform 2:1:1, and they worsen the underlying imbalance problem.

BCAAs are the amino acid category whose reputation has changed most in recent years. They dominated sports nutrition for two decades, and improved research has substantially undermined the case for them as a standalone product.

The proposed mechanism runs through leucine's activation of mTORC1 and the initiation of muscle protein synthesis, with isoleucine and valine contributing to glucose uptake and to the amino acid pool.

The flaw is straightforward. Building muscle protein requires all the essential amino acids. Supplying three of nine triggers the signal to build but leaves six missing. The body responds by breaking down existing muscle protein to source them, which is close to self-defeating.

A separate proposed mechanism concerns central fatigue: BCAAs compete with tryptophan for transport into the brain, potentially reducing serotonin synthesis during endurance work. This is more plausible than the muscle-building rationale, but it is not what BCAAs are usually sold for.

Studies measuring muscle protein synthesis have found that BCAAs alone produce a substantially smaller response than whey protein containing the same amount of leucine. The missing amino acids are the limiting factor, exactly as the mechanism predicts.

Trials on muscle mass and strength in people already consuming adequate protein have generally found no benefit from added BCAAs. Reviews of the literature have been consistently unfavourable, and several prominent researchers have argued the case for BCAA supplementation in fed individuals is effectively closed.

Evidence for reduced muscle soreness is somewhat better, with several trials reporting modest reductions after damaging exercise. Where BCAAs may retain a role is training fasted, or in situations where total protein intake is genuinely low, but in both cases EAAs or whey would do the job better.

BCAAs are well tolerated and are ordinary dietary components. Digestive discomfort is occasionally reported at higher doses, and unflavoured powder is notably bitter.

The amino acid competition point deserves attention. Large isolated BCAA doses reduce tryptophan and tyrosine transport into the brain. Some users report low mood or flatness with sustained heavy use, which is consistent with reduced availability of those neurotransmitter precursors, though it is not well characterised in trials.

Anyone who has been advised to restrict specific amino acids in their diet should avoid BCAA products entirely. Anyone taking regular medication should check before use.